Four-Year Outcomes From a Prospective Phase II Clinical Trial of Moderately Hypofractionated Proton Therapy for Localized Prostate Cancer

Grewal, A.; Schonewolf, Caitlin; Min, Eun Jeong; Chao, Hann‐Hsiang; Both, Stefan; Lam, S.; Mazzoni, Susan; Bekelman, Justin E.; Christodouleas, John P.; Vapiwala, Neha

doi:10.1016/j.ijrobp.2019.05.069

Cited by 35 publications

(39 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this singleinstitutional experience, 184 men were treated with 70 Gy in 2.5 Gy fractions. 15 With median follow-up of 49.2 months, the authors found that treatment was well tolerated with 3.8% and 12.5% acute grade 2þ GI/GU toxicity, respectively. Similarly, the 4-year incidence of late grade 2þ GI/GU toxicity was 13.6% and 7.6%, respectively.…”

mentioning

confidence: 95%

Hypofractionation in Prostate Cancer Using Proton Beam

Quinn

Hamstra

2019

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

mentioning

confidence: 95%

Hypofractionation in Prostate Cancer Using Proton Beam

Quinn

Hamstra

2019

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

“…While these results were better for HFPT as compared with conventionally fractionated PBT, the absolute rates are quite comparable as reported in photon based hypofractionated studies. [20][21][22] These findings were corroborated in the single arm phase-2 study 24 on HFPT for low-and intermediate-risk CaP.…”

Section: Biology Of Proton Beam Therapymentioning

confidence: 53%

Role of Proton Beam Therapy in Current Day Radiation Oncology Practice

Saini

Shukla

Sood

et al. 2020

ASJO

View full text Add to dashboard Cite

Proton beam therapy (PBT), because of its unique physics of no–exit dose deposition in the tissue, is an exciting prospect. The phenomenon of Bragg peak allows protons to deposit their almost entire energy towards the end of the path of the proton and stops any further dose delivery. Braggs peak equips PBT with superior dosimetric advantage over photons or electrons because PBT doesn’t traverse the target/body but is stopped sharply at an energy dependent depth in the target/body. It also has no exit dose. Because of no exit dose and normal tissue sparing, PBT is hailed for its potential to bring superior outcomes. Pediatric malignancies is the most common malignancy where PBT have found utmost application. Nowadays, PBT is also being used in the treatment of other malignancies such as carcinoma prostate, carcinoma breast, head and neck malignancies, and gastrointestinal (GI) malignancies. Despite advantages of PBT, there is not only a high cost of setting up of PBT centers but also a lack of definitive phase-III data. Therefore, we review the role of PBT in current day practice of oncology to bring out the nuances that must guide the practice to choose suitable patients for PBT.

show abstract

“…In Japan, proton beam therapy is mainly used for liver cancer, lung cancer, esophageal cancer, and prostate cancer in adults [ 15 , 16 , 17 , 18 , 19 ]. Radiotherapy for hepatocellular carcinoma was previously considered only for palliative treatment.…”

Section: Discussionmentioning

confidence: 99%

An Analysis of Vertebral Body Growth after Proton Beam Therapy for Pediatric Cancer

Baba

Mizumoto

Oshiro

et al. 2021

Cancers

View full text Add to dashboard Cite

Impairment of bone growth after radiotherapy for pediatric bone cancer is a well-known adverse event. However, there is limited understanding of the relationship between bone growth and irradiation dose. In this study, we retrospectively analyzed bone growth impairment after proton beam therapy for pediatric cancer. A total of 353 vertebral bodies in 23 patients under 12 years old who received proton beam therapy were evaluated. Compared to the non-irradiated vertebral body growth rate, the irradiated vertebral body rate (%/year) was significantly lower: 77.2%, 57.6%, 40.8%, 26.4%, and 14.1% at 10, 20, 30, 40, and 50 Gy (RBE) irradiation, respectively. In multivariate analysis, radiation dose was the only factor correlated with vertebral body growth. Age, gender, and vertebral body site were not significant factors. These results suggest that the growth rate of the vertebral body is dose-dependent and decreases even at a low irradiated dose. This is the first report to show that proton beam therapy has the same growth inhibitory effect as photon radiotherapy within the irradiated field.

show abstract

Four-Year Outcomes From a Prospective Phase II Clinical Trial of Moderately Hypofractionated Proton Therapy for Localized Prostate Cancer

Cited by 35 publications

References 30 publications

Hypofractionation in Prostate Cancer Using Proton Beam

Hypofractionation in Prostate Cancer Using Proton Beam

Role of Proton Beam Therapy in Current Day Radiation Oncology Practice

An Analysis of Vertebral Body Growth after Proton Beam Therapy for Pediatric Cancer

Contact Info

Product

Resources

About